아프레아 테라퓨틱스APRE 주가

Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing

Aprea Therapeutics Inc: Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing...

[424B7] 424B7 — 424B7

[SCHEDULE 13G] SCHEDULE 13G

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.

Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher

Aprea Therapeutics (APRE) reports Q1 2026 results with a narrow EPS beat, strong $46.5M cash position, and promising APR-1051 clinical data ahead of ASCO 2026.

Earnings Scheduled For May 13, 2026

Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 66.67 percent increase over losses of $(0.66) per share from

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the...

[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q